BridgeMD
New treatment option for Ischemic Heart Disease
Official title Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery
ClinicalTrials.gov ID: NCT05632432
What this study is testing
- What it's testing
- Ischemic heart disease (IHD) leads the global mortality statistics. Atherosclerotic plaques in coronary arteries hallmark IHD, drive hypoxia, and may rupture to result in myocardial infarction (MI) and death of contractile cardiac muscle, which is eventually replaced by a scar.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Informed consent obtained
- Left ventricular ejection fraction (LVEF) between ≥ 15% and ≤ 40% at recruitment (transthoracic echocardiography)
- New York Heart Association (NYHA) Class II-IV heart failure symptoms
You likely can't join if
- Heart failure due to left ventricular outflow tract obstruction
- Acute myocardial infarction (AMI) within last 30 days
- History of life-threatening and possibly repeating ventricular arrhythmias or resuscitation, or an implantable cardioverter-defibrillator
- Stroke or other disabling condition within 3 months before screening
- Severe valve disease or scheduled valve surgery
- Renal dysfunction (GFR \<45 ml/min/1.73m2)
See the full eligibility criteria
- Informed consent obtained
- Left ventricular ejection fraction (LVEF) between ≥ 15% and ≤ 40% at recruitment (transthoracic echocardiography)
- New York Heart Association (NYHA) Class II-IV heart failure symptoms
- Heart failure due to left ventricular outflow tract obstruction
- Acute myocardial infarction (AMI) within last 30 days
- History of life-threatening and possibly repeating ventricular arrhythmias or resuscitation, or an implantable cardioverter-defibrillator
- Stroke or other disabling condition within 3 months before screening
- Severe valve disease or scheduled valve surgery
- Renal dysfunction (GFR \<45 ml/min/1.73m2)
- Other disease limiting life expectancy
- Contraindications for coronary angiogram or LGE-CMRI
- Participation in some other clinical trial Screening Failure:
- After optimization of medications, no visible scar or LVEF ≥ 50% in preoperative LGE-CMRI
- Preoperative LGE-CMRI has not been performed prior scheduled CABG
The study team makes the final eligibility decision.
Where it's taking place
- Helsinki, Uusimaa, Finland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Helsinki, Uusimaa, Finland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.